SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, is pleased to announce that Tim Miller is joining the Company as Director of Investor Relations and Capital Markets, effective November 1, 2023. Mr. Miller will be based out of the Company’s Toronto office and brings a wealth of knowledge, experience and expertise to his new role with ZYUS, making him a valuable addition to the team.
Mr. Miller is a distinguished professional with a Bachelor of Commerce degree from Ryerson University, boasting an impressive track record of nearly two decades as a capital markets executive. His core focus has been Institutional Equity Sales, and his expertise extends across a broad spectrum of clients. These encompass a wide range, from US and Canadian family offices to hedge funds, pension funds, mutual funds, venture capital firms, and private equity investors.
"We are extremely pleased to welcome Mr. Miller to ZYUS,” said Brent Zettl, President and Chief Executive Officer of the Company. "As we advance our clinical research activities and further our operations, it’s vital that we continue to foster robust relationships within the investment community, highlighting ZYUS' commitment to innovation and drug development. Mr. Miller brings extensive knowledge to ZYUS, coupled with his expertise in the capital markets and established relationships within the investment community, making him exceptionally well-suited to lead our investor relations function.”
"I am pleased to join ZYUS, and I look forward to collaborating with the team to help create shareholder value and drive the Company's growth and success," said Mr. Miller.
About ZYUS Life Sciences Corporation
ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of regulated cannabinoid-based pharmaceutical drug product candidates. Through clinical research, ZYUS is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, ZYUS is dedicated to delivering high quality, cGMP/EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The ZYUS vision is to reimagine the potential of pain therapeutics by pursuing regulatory approval of cannabinoid formulations and elevating cannabinoids as a standard of care in pursuit of transformational impact on patients’ lives. ZYUS: Advancing the Science of Well-Being. For additional information, visit www.zyus.com or follow us on X (formerly known as Twitter) @ZYUSCorp.
Cautionary Note Regarding Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the Company’s business, the Company’s ability to advance clinical research activities and further operations, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates, introduce products that act as alternatives to current pain management therapies and foster robust relationships within the investment community. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company’s business, the Company’s ability to advance clinical research activities and further operations, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates, introduce products that act as alternatives to current pain management therapies and foster robust relationships within the investment community are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the Company will be able to advance its clinical research activities and further operations, realize its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates, introduce products that act as alternatives to current pain management therapies or foster robust relationships within the investment community. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
